52 related articles for article (PubMed ID: 19922135)
1. Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis.
Zhang Y; Wang L; Fu Y; Song H; Zhao H; Deng M; Zhang J; Fan D
Amyotroph Lateral Scler; 2009; 10(5-6):430-1. PubMed ID: 19922135
[TBL] [Abstract][Full Text] [Related]
2. TNF - a potential therapeutic target for ALS.
Wood H
Nat Rev Neurol; 2022 Jun; 18(6):317. PubMed ID: 35534550
[No Abstract] [Full Text] [Related]
3. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study.
Chiò A; Mora G; La Bella V; Caponnetto C; Mancardi G; Sabatelli M; Siciliano G; Silani V; Corbo M; Moglia C; Calvo A; Mutani R; Rutella S; Gualandi F; Melazzini M; Scimè R; Petrini M; Bondesan P; Garbelli S; Mantovani S; Bendotti C; Tarella C;
Muscle Nerve; 2011 Feb; 43(2):189-95. PubMed ID: 21254083
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-colony stimulating factor (G-CSF): an emerging therapeutic approach for amyotrophic lateral sclerosis (ALS).
Vafaei Mastanabad M; Nooraei A; Hassan Zadeh Tabatabaei MS; Akbari Fakhrabadi A; Jafarzadeh F
Acta Neurol Belg; 2023 Jun; 123(3):763-771. PubMed ID: 35737276
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapies for Neurodegenerative Diseases.
Mortada I; Farah R; Nabha S; Ojcius DM; Fares Y; Almawi WY; Sadier NS
Front Neurol; 2021; 12():654739. PubMed ID: 34163421
[TBL] [Abstract][Full Text] [Related]
6. The role of G-CSF neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE): current status.
Dumbuya JS; Chen L; Wu JY; Wang B
J Neuroinflammation; 2021 Feb; 18(1):55. PubMed ID: 33612099
[TBL] [Abstract][Full Text] [Related]
7. Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates.
Gouel F; Rolland AS; Devedjian JC; Burnouf T; Devos D
Front Neurol; 2019; 10():835. PubMed ID: 31428042
[TBL] [Abstract][Full Text] [Related]
8. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.
Goutman SA; Savelieff MG; Sakowski SA; Feldman EL
Expert Opin Investig Drugs; 2019 Jun; 28(6):525-543. PubMed ID: 31189354
[TBL] [Abstract][Full Text] [Related]
9. Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients.
Johannesen S; Budeus B; Peters S; Iberl S; Meyer AL; Kammermaier T; Wirkert E; Bruun TH; Samara VC; Schulte-Mattler W; Herr W; Schneider A; Grassinger J; Bogdahn U
Front Neurol; 2018; 9():971. PubMed ID: 30534107
[No Abstract] [Full Text] [Related]
10. Longitudinal Diffusion Tensor Imaging-Based Assessment of Tract Alterations: An Application to Amyotrophic Lateral Sclerosis.
Baldaranov D; Khomenko A; Kobor I; Bogdahn U; Gorges M; Kassubek J; Müller HP
Front Hum Neurosci; 2017; 11():567. PubMed ID: 29259550
[No Abstract] [Full Text] [Related]
11. Granulocyte Colony-Stimulating Factor (G-CSF) for the Treatment of Spinal Cord Injury.
Khorasanizadeh M; Eskian M; Vaccaro AR; Rahimi-Movaghar V
CNS Drugs; 2017 Nov; 31(11):911-937. PubMed ID: 29063471
[TBL] [Abstract][Full Text] [Related]
12. Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.
Khalid SI; Ampie L; Kelly R; Ladha SS; Dardis C
Front Neurol; 2017; 8():486. PubMed ID: 28993751
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the levels of CSF and serum factors in ALS.
Guo J; Yang X; Gao L; Zang D
Brain Behav; 2017 Mar; 7(3):e00637. PubMed ID: 28293476
[TBL] [Abstract][Full Text] [Related]
14. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.
Chen KS; Sakowski SA; Feldman EL
Ann Neurol; 2016 Mar; 79(3):342-53. PubMed ID: 26696091
[TBL] [Abstract][Full Text] [Related]
15. The Granulocyte-colony stimulating factor has a dual role in neuronal and vascular plasticity.
Wallner S; Peters S; Pitzer C; Resch H; Bogdahn U; Schneider A
Front Cell Dev Biol; 2015; 3():48. PubMed ID: 26301221
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled study of Iranian patients.
Amirzagar N; Nafissi S; Tafakhori A; Modabbernia A; Amirzargar A; Ghaffarpour M; Siroos B; Harirchian MH
J Clin Neurol; 2015 Apr; 11(2):164-71. PubMed ID: 25851895
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis.
Goutman SA; Chen KS; Feldman EL
Neurotherapeutics; 2015 Apr; 12(2):428-48. PubMed ID: 25776222
[TBL] [Abstract][Full Text] [Related]
18. Gene expression changes in spinal motoneurons of the SOD1(G93A) transgenic model for ALS after treatment with G-CSF.
Henriques A; Kastner S; Chatzikonstantinou E; Pitzer C; Plaas C; Kirsch F; Wafzig O; Krüger C; Spoelgen R; Gonzalez De Aguilar JL; Gretz N; Schneider A
Front Cell Neurosci; 2014; 8():464. PubMed ID: 25653590
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow-derived cell mobilization by G-CSF to enhance osseointegration of bone substitute in high tibial osteotomy.
Marmotti A; Castoldi F; Rossi R; Marenco S; Risso A; Ruella M; Tron A; Borrè A; Blonna D; Tarella C
Knee Surg Sports Traumatol Arthrosc; 2013 Jan; 21(1):237-48. PubMed ID: 22872005
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial.
Takahashi H; Yamazaki M; Okawa A; Sakuma T; Kato K; Hashimoto M; Hayashi K; Furuya T; Fujiyoshi T; Kawabe J; Yamauchi T; Mannoji C; Miyashita T; Kadota R; Hashimoto M; Ito Y; Takahashi K; Koda M
Eur Spine J; 2012 Dec; 21(12):2580-7. PubMed ID: 22391867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
